EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7 ‐ H3

Aya Saleh, Nitzan Medina-Itzhaki, Milena Chekov, Eden Gal-Swisa, Roba Gabesh-Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger und 1 weitere

Molecular Oncology · 2026

DOI: 10.1002/1878-0261.70235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Aya Saleh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa, Israel. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cell Movement, B7 Antigens, Cystadenocarcinoma, Serous. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU's Marie Curie Actions (FP7 People)‎, Women's Health Fund at the Rambam Health Care Campus‎, Len and Susan Mark Phase II initiative for Ovarian and Uterine/MMMT grant, the Israel ‎Cancer Research Fund ‎.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paired box protein Pax‐8 ( PAX8 ) is a critical lineage marker and master regulator of transcription in high‐grade serous ovarian carcinoma (HGSC)—the most common subtype of epithelial ovarian cancer—driving cell proliferation and migration and resisting apoptosis. This study aimed to elucidate the mechanism of action of PAX8 in this disease. By performing an unbiased analysis of PAX8‐regulated genes, we discovered two PAX8‐regulated genes—coiled‐coil domain‐containing protein 80 ( CCDC80 ) and cluster of differentiation 276 ( CD276 ) antigen (also known as B7‐H3)—that mediate PAX8 activity and play key cancer cell autonomous roles in this disease. Our findings indicate that PAX8 negatively regulates CCDC80 , a novel cell autonomous tumor suppressor in HGSC. We demonstrate that CCDC80, localized to the nucleus, significantly reduces HGSC tumor growth and metastasis in vivo in a mouse model. Notably, CCDC80 exerts its function by suppressing the expression of the immune checkpoint protein B7‐H3. However, in HGSC, B7‐H3 is predominantly cytoplasmic and promotes HGSC proliferation and migration independent of its immune role. Additionally, PAX8 positively regulates B7‐H3 expression in a CCDC80‐independent manner, underscoring the multifaceted oncogenic role of PAX8. This study highlights the complex regulatory network involving PAX8, CCDC80, and B7‐H3 in HGSC progression. Targeting this signaling pathway may provide a novel therapeutic strategy to improve treatment outcomes for patients with epithelial ovarian cancer. B7‐H3, which is currently targeted in clinical trials, shows promise as HGSC target for therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCell MovementB7 AntigensCystadenocarcinoma, SerousFemaleHumansAnimalsCell Line, TumorPAX8 Transcription FactorCell ProliferationGene Expression Regulation, NeoplasticMiceMice, NudeNeoplasm Grading

Stichwörter der Autor:innen

B7‐H3CCDC80Ovarian cancerPAX8Tumor suppressor, Migration

Substanzen

CD276 protein, humanB7 AntigensPAX8 Transcription FactorPAX8 protein, human

Autor:innen und Institutionen

  • Division of Oncology, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa, Israel.
  • Women's Cancers Research Lab, Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
  • Department of Pathology, Rambam Health Care Campus, Haifa, Israel.
  • Department of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Illinois, USA.

ORCID-Profile: Ruth Perets

Förderung

  • EU's Marie Curie Actions (FP7 People)‎
  • Women's Health Fund at the Rambam Health Care Campus‎
  • Len and Susan Mark Phase II initiative for Ovarian and Uterine/MMMT grant, the Israel ‎Cancer Research Fund ‎
  • Beverly Librach Abshez Initiative for Ovarian and Female Reproductive System Cancers, Israel Cancer Research Fund
  • Israel Cancer Association's USA Board of Directors grant‎
  • Israel Science Foundation
  • FP7 People: Marie-Curie Actions

Zitieren

APA

Saleh, A., Medina-Itzhaki, N., Chekov, M., Gal-Swisa, E., Gabesh-Wahabi, R., Savyon, I., Naroditsky, I., Kenny, H. A., Fares, B., Korsensky, L., Girsh, E., Berger, L., & Perets, R. (2026). CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7 ‐ H3. Molecular Oncology. https://doi.org/10.1002/1878-0261.70235

Vancouver

Saleh A, Medina-Itzhaki N, Chekov M, Gal-Swisa E, Gabesh-Wahabi R, Savyon I, et al. CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7 ‐ H3. Molecular Oncology. 2026. doi:10.1002/1878-0261.70235

BibTeX
@article{Saleh2026,
  author = {Saleh, Aya and Medina-Itzhaki, Nitzan and Chekov, Milena and Gal-Swisa, Eden and Gabesh-Wahabi, Roba and Savyon, Inbar and Naroditsky, Inna and Kenny, Hilary A and Fares, Basem and Korsensky, Lina and Girsh, Einav and Berger, Liron and Perets, Ruth},
  title = {CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7 ‐ H3},
  journal = {Molecular Oncology},
  year = {2026},
  doi = {10.1002/1878-0261.70235}
}
Kostenlos starten →